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Abstract
The epidemiology of vaccine-preventable diseases is a result of numerous
factors, among which organized active immunization is one of the most im-
portant. Analysis of trends in disease incidence of vaccine-preventable
diseases is an adequate way to provide evidence of impact of vaccination on
disease burden.
In this manuscript, trends in vaccine-preventable diseases in Croatia are
analyzed. Due to high vaccination coverage with safe and efficacious
vaccines, some diseases like poliomyelitis and diphtheria have been elimi-
nated in Croatia, while measles and rubella are at the point of elimination
and burden of other vaccine-preventable diseases has been reduced signifi-
cantly. Until recently, most of the vaccines used in the national immuniza-
tion schedule have been produced by the Institute of Immunology, Zagreb,
and the reduction of disease incidence is largely attributable to the Institu-
te’s vaccines. This especially refers to the Koprowski oral polio vaccine,
measles, mumps, rubella and diphtheria, tetanus, pertussis vaccines.
INTRODUCTION
The epidemiology of vaccine-preventable diseases is a result of nu-merous factors, among which organized active immunization is
one of the most important. Therefore, analysis of trends in disease
incidence of vaccine-preventable diseases is an adequate way to provide
evidence of impact of vaccination on disease burden. This especially
applies to air-borne diseases whose incidence cannot be influenced by
improved sanitation and living conditions. Some opponents of vacci-
nation may argue that active immunization does not have a significant
impact on disease burden because some food-borne illnesses as typhoid
fever and hepatitis A are eliminated or have declined significantly re-
gardless of vaccination due to access to safe drinking water, improved
waste-water management, personal hygiene, control of food-handling
processes, use of antibiotics and nutrition status of the population. How-
ever, none of these factors have any real impact on diseases transmitted
by the respiratory route, so analysis of trends of measles, mumps, rubella
and pertussis provides a direct measure of the value of immunization.
For diseases which are mainly transmitted by faecal-oral mode, like
poliomyelitis, improved sanitation and living conditions definitely do
have an impact on disease burden, however, wide-scale immunization
has proved to accelerate disease elimination significantly.
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overview
Thanks to availability of effective, safe and low-cost
vaccines for some of the communicable diseases which
represented significant health burden to the community
in the pre-vaccine era and to wide-scale usage of vacci-
nes, the morbidity of these diseases has been reduced
significantly. This encouraged the international public
health community to aim at global eradication and eli-
mination of certain diseases. The World Health Orga-
nization (WHO) has set goals to eradicate poliomyelitis
globally and eliminate measles and congenital rubella
regionally. The time-frame for achieving these goals has
had to be prolonged due to inadequate vaccine coverage
in endemic countries. Global eradication of poliomye-
litis was first anticipated to be achieved by year 2000, but
has been postponed to year 2018 (1, 2).
The Global Measles and Rubella Strategic Plan aims
to achieve measles and rubella elimination in at least five
WHO regions by 2020 (3). Elimination of measles and
congenital rubella has been set for 2010 in the European
region (4), but had to be prolonged to 2015 due to inade-
quate vaccination coverage in many European countries
which are still experiencing huge outbreaks of measles
among unvaccinated persons (5, 6).
Croatia has been fortunate to have a reliable vaccine
producer, which assured access to affordable, efficacious
and safe vaccines and a well organized immunization
delivery system, which resulted in eradication of polio-
myelitis and virtual elimination of rubella and measles.
The Institute of Immunology Zagreb (Institute) has
been supplying the national immunization programme
with the respective vaccines since the introduction of
diphtheria vaccination in 1948, tetanus vaccination in
1955, pertussis vaccination in 1959, poliomyelitis vacci-
nation in 1961, measles vaccination in 1968, rubella vacci-
nation in 1975 and mumps vaccination in 1976. Other
vaccines included in the childhood immunization pro-
gramme (BCG, hepatitis B, Haemophilus influenzae
type B and combination vaccines containing acellular
pertussis) are produced by foreign manufacturers. In
order assess the value of vaccines produced by the Insti-
tute of Immunology, an analysis of trends of targeted
vaccine-preventable diseases is presented in this paper.
MATERIALS AND METHODS
Data on disease incidence in Croatia originate from
routine infectious disease surveillance system. Reporting
of communicable diseases is mandatory in Croatia ac-
cording to the Act on Protection against Communicable
Diseases (7, 8). Since the list of diseases has been updat-
ed gradually, data on some diseases exist since the period
between two world wars, while for others data are avail-
able for one, two or a few decades.
All health care providers who diagnose a communi-
cable disease from the list of reportable diseases are oblig-
ed to report it on a standardized form to a local epidemio-
logy unit, according to the place of residence of a patient.
A local epidemiologist is responsible for conducting an
epidemiological investigation following a report, inter-
vention, if required, and runs a registry of communic-
able disease reports for the territory under his/her res-
ponsibility. By sending reports to the local epidemiologist,
according to the patients’ home address, duplications of
reports are avoided. The local epidemiologist also sends
the report to the county Institute of Public Health and to
the Croatian National Institute of Public Health (CNIPH).
The CNIPH receives 60 000 to 70 000 individual reports
per year. At each level: local, county and national, the
reports are analyzed on a daily basis and control mea-
sures implemented if needed.
Reports of adverse events following immunization are
handled in a similar way, also based on the same law and
respective bylaws. According to the Act on Protection
against Communicable Diseases, healthcare providers
who identify an adverse event following immunization
should report it to the CNIPH and, according to the Act
on medicines, adverse events should also be reported to
the Croatian Agency for Medicines and Medical Products
(CAMMP) (9). In reality, health-care workers (HCWs)
usually report adverse events to the local epidemiologist
or county Institute of Public Health and to the CNIPH
or CAMMP. In order to make sure the CNIPH and
CAMMP both receive and analyze the reports, a working
group on adverse events following immunization, con-
sisting of experts from the CNIPH and the CAMMP
meets twice a month in order to exchange received re-
ports and discuss each individual report.
Information on vaccination coverage is also regulated
by the Act on Protection against Communicable Disea-
ses and respective bylaws and is collected and analyzed
annually at all levels. The most important bylaw, which
regulates reporting on immunization coverage, is the
Ordinance on the National Immunization Schedule for
Croatia, which is issued by the minister of health an-
nually.
Therefore, all prerequisites for evaluation of the na-
tional immunization programme are fulfilled: disease
surveillance, adverse events following immunization sur-
veillance and vaccination coverage monitoring.
The analyses presented in this paper are based on the
data collected and compiled by the Croatian National
institute of Public Health.
RESULTS
Diphtheria
Vaccination against diphtheria was introduced into
the mandatory childhood vaccination schedule in 1948.
In the first years following the introduction of vaccina-
tion, no effect on disease incidence was observed due to
unsatisfactory vaccination coverage. A few years after
introduction, due to improved vaccination coverage, the
incidence of disease declined steadily until the seventies,
with the last case of diphtheria recorded in Croatia in
1974 (Figure 1.). The vaccine produced by the Institute
was used for primary vaccination and boosters through-
out childhood and school age, until the eighth grade of
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elementary school up to 1995. Following large outbreaks
of diphtheria in Eastern Europe during the 1990s, an
additional booster dose was added into the national im-
munization schedule for 18-year old children in 1995.
Due to high immunization coverage, Croatia was not
affected by the resurgence of diphtheria in the 1990s.
Additionally, a seroprevalence study in the Croatian po-
pulation born between 1934 and 1974 was performed in
1994 (10). All study participants (N=223) had anti-
-diphtheria toxin antibodies above the minimum protec-
tive level of 0.01 IU/ml measured by enzyme-linked
immunosorbent assay (ELISA) and neutralization test
(NT). Interestingly, persons born between 1964 and 1974
had highest geometric mean titres (GMT) of antibodies
and the GMT declined towards older age groups, indi-
cating waning immunity. The results of this study also
indicate that immunity conferred by the vaccine used in
Croatia is not inferior to immunity conferred by natural
contact with the bacteria, since the age group with the
highest GMTs had a much lower chance to be in contact
with C. diphtheriae than the older age groups. This same
vaccine is still used in Croatia for diphtheria booster
immunization at seven, fourteen and eighteen years of
age. The vaccine has shown an excellent safety profile,
with local reactions at the injection site being the majo-
rity of reported adverse events following immunization.
Tetanus
Vaccination against tetanus was introduced into the
vaccination schedule in 1955. From the beginning of
tetanus immunization, combination vaccine produced
by the Institute and consisting of diphtheria and tetanus
toxoids were used in infants and pre-school children.
Pertussis was later added to the combination vaccine for
infants and pre-school children. For school-aged children,
a tetanus-diphtheria combination vaccine with a lesser
amount of diphtheria toxoid is used.
The incidence of tetanus in Croatia is presented in
Figure 2.
Besides reduction in tetanus incidence, a significant
shift of morbidity to older age groups occurred. At the
time before introduction of the vaccine into the immuni-
zation programme during the 1940s and 1950s, tetanus
patients were predominantly working-age men, while in
the past ten years virtually all patients were unvaccinated
women older than 60 years. In order to address older
persons who were born before the introduction of teta-
nus vaccination, immunization of 60-year old persons
was added to the immunization programme in 2002.
Figure 3 illustrates the significant change in the age
structure of tetanus patients in Croatia, which was the
basis for the decision to add immunization of 60-year old
persons.
Neonatal tetanus has been eliminated due to high
vaccination coverage among women of child-bearing age.
Combined diphtheria-tetanus vaccine produced by
the Institute is still used in Croatia for immunization of
school-aged children.
The vaccine has shown an excellent safety profile, with
local reactions at the injection site being the majority of
reported adverse events following immunization.
Pertussis
Following the introduction of pertussis vaccine into
immunization programme, a sharp and steady decline in
pertussis incidence was observed, as shown in Figure 4.
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Figure 2. Incidence of tetanus in Croatia in the 1946-2011 period.Figure 1. Incidence of diphtheria in Croatia in the 1945-2011 period.
Age distribution of tetanus cases in Croatia
Comparison of the time period before introduction of universal
immunization and the period prior to introduction of






































Figure 3. Age distribution of tetanus cases in Croatia, comparison of
the 1953-1954 period with the 1998-2001 period.
The vaccine responsible for this high impact on disease
incidence is combined whole-cell diphtheria-tetanus-per-
tussis vaccine produced by the Institute. The incidence
of pertussis declined from an annual average of 5000
cases at the time of vaccine introduction to less than 100
casses per year in the last decade. Most pertussis cases in
the last decade are infants who are too young to be
protected by vaccination.
In 2008, due to adding additional injectable vaccines
to the pre-school immunization schedule (adding hepa-
titis B vaccination to infants and switching from OPV to
IPV), the Institute’s DTP vaccine was replaced by a
combination vaccine containing diphtheria, tetanus, acel-
lular pertussis, inactivated polio and Hib (DTP-IPV-
-Hib) in order to reduce the number of injectins in
infancy and early childhood. This was a compromise in
which a possibly less efficacious pertussis vaccine was
introduced in order to ensure compliance with the im-
munization schedule. Four years of use of the acellular
pertussis vaccine are still a too short period to evaluate
the impact of switching from the highly efficacious whole-
-cell pertussis vaccine to acellular pertussis vaccine.
Adverse events attributable to the whole-cell pertussis
component of the Institute’s DTP vaccine have been
reported rarely, mostly being inconsolable crying, while
for the majority of reported adverse events (induration,
redness and swelling at the injection site) it is not pos-
sible to discern to which component of the combination
vaccine the local reaction is attributable. There have
been no reports of long term neurological consequences
following administration of this DTP vaccine in Croatia.
Poliomyelitis
In 1961, another highly efficacious vaccine produced
by the Institute was added to the immunization pro-
gramme in Croatia. The Koprowski live polio vaccine
(OPV) was introduced through a wide range immuni-
zation campaign, during which the entire Croatian po-
pulation between three months and 20 years received
OPV in two rounds of vaccination during 1961–1962.
After the campaign, immunization of infants with boo-
sters in pre-school and school-aged childred continued
on a routine basis. The vaccine produced by the Institute
was used until 1983 when it was replaced by Sabin OPV.
In 2008 OPV was replaced by inactivated polio vaccine
(IPV). Annually, there were tens to few hundreds of cases
reported before the introduction of vaccination. Imme-
diately after the mass vaccination campaign, the number
of poliomyelitis cases dropped below ten per year, as
illustrated in Figure 5. The last case of poliomyelitis in
Croatia was reported in 1989, following a ten-year period
with an average annual incidence below one case per year.
Therefore, the elimination of poliomyelitis was achieved
with the Institute’s vaccine. After the elimination of po-
liomyelitis, additional enhanced acute flaccid paralysis
surveillance and environmental surveillance have taken
place in order to document eradication of poliovirus
from the population. In 2002, the European region of
WHO was declared polio-free. On this occasion, a small
number of individuals, experts and professionals who
were recognized as most deserving for this success re-
ceived certificates from WHO for dedicated work on
polio eradication and contribution to the elimination of
polio from the European region. One of the four reci-
pients in Croatia who also received brass polio eradica-
tion pins for exceptional contribution was Drago Iki},
full member of the Croatian Academy of Sciences and
Arts, involved in the development and testing of the
Koprowski OPV produced by the Institute of Immuno-
logy, Zagreb.
Measles
Measles vaccine, produced from the further attenuat-
ed Edmonston-Zagreb strain by the Institute of Immu-
nology was introduced into the immunization program-
me in 1968. In the beginning it was used as a monovalent
measles vaccine, for the first and second dose. In 1976 a
trivalent measles-mumps-rubella vaccine produced by
the Institute replaced the monovalent vaccine for the first
dose, and since 1994 trivalent vaccine was used also for
the second dose. Due to adverse events caused by the
mumps component of MMR, which occurred after the
first dose of vaccine, this vaccine was replaced for the first
dose by one of another producer in 2009. In 2011 this
vaccine was replaced by another for the second dose, due
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Figure 5. Incidence of poliomyelitis in Croatia in the 1945-2011 period.
Figure 4. Incidence of pertussis in the Croatia 1949-2011 period.
to discontinuation of its production. The results of four
decades of using the Edmonston-Zagreb measles strain
in Croatia are illustrated in Figure 6. Immediately after
the introduction of measles vaccine into the immuni-
zation programme, the incidence declined to a range of
1000 to 7000 cases per year, compared to a range of 6000
to 16000 cases per year prior to vacccine introduction,
and the interval between peak incidence years increased.
With improved vaccination coverage during the 1990s,
measles incidence further declined and never exceeded
hundred cases per year since 1999. Actually, during the
last decade only sporadic imported cases occurred, except
for three small outbreaks involving mostly unvaccinated
adults which followed importation of measles in years
2003/2004, 2008 and 2011 with 73, 51 and 12 cases in-
volved, respectively. In the early years of measles vaccina-
tion, numerous field trials and observational studies con-
firmed the immunogenicity, effectiveness and safety of
the Edmonston-Zagreb measles vaccine (11, 12, 13, 14,
15, 16).
Based on the fact that the three small outbreaks in the
last decade were easily controlled and that in the years
between the outbreaks we did not see indigenous cases of
measles, we may say that the use of Edmonston-Zagreb
based measles vaccine resulted in elimination of measles
in Croatia. The vaccine has shown to have a very good
safety profile, with only a few adverse events reported
annually which are likely to be attributed to the measles
component of the MMR vaccine (e.g. morbilliform rash,
purpura)
Rubella
Rubella vaccination was added to the childhood im-
munization programme in 1975, administered with the
measles vaccine at the age of 12 months for all children
and at the age of 14 as a monovalent vaccine only for
girls. The following year, in 1976, it was given as part of
an MMR combination vaccine at the age of 12 months,
while it wasn’t before 1994 that it was decided to give a
second dose of rubella vaccine as part of combined MMR
to all children, not only girls. Throughout the entire
period, RA27/3 strain, produced by the Institute, has
been used. More than 35 years of universal immuniza-
tion resulted in virtual elimination of rubella in Croatia
as illustrated in Figure 7.
The incidence of rubella decreased from several thou-
sand cases at the time of vaccine introduction to sporadic
imported cases in the last decade, with less than ten
reports per year, with only one exception: a small out-
break of rubella among unvaccinated adolescents in Du-
brovnik during 2007 with 39 cases.
Adverse events attributable to the rubella component
of combined MMR vaccine (e.g. rubelliform rash,
arthralgia) have been reported sporadically.
Mumps
Mumps vaccine, produced from the futher attenuated
Leningrad-Zagreb strain was introduced into the im-
munization programme in 1976 as part of the trivalent
MMR vaccine at the age of 12 months. In 1994 a second
dose was added to the schedule at the age of six years.
Although a significant success has been achieved in re-
ducing the incidence of mumps, the reduction is slightly
less remarkable than in the case of measles and rubella.
In fact, epidemiological situation regarding mumps is
similar to the one we had with measles and rubella at the
turn of the century, just before the elimination phase.
During the last decade, we had fourty to hundred-fifty
indigenous mumps cases annually, compared to thou-
sands of cases at the time of vaccine introduction, which
is illustrated in Figure 8. The safety issue of this vaccine
has been a matter of controversy in the last fifteen years.
The mumps component of the combined MMR vaccine
was responsible for tens of vaccine associated cases of
parotitis annually and ten to twenty cases of aseptic
meningitis. Due to the relatively mild symptomatology
of both adverse events, it was acceptable to use this vac-
cine at the time of high incidence of mumps in the
community. However, in the last decade, the incidence of
vaccine associated mumps outnumbered the cases of
naturally acquired mumps in some years. Regardless of
the mentioned safety issues, the vaccine was not replaced
in the immunization programme until a new adverse
event was recognized. In late 2007 and during 2008,
there were more than twenty reports of transmission of
the vaccine virus to those in contact with the vaccinated,
resulting in illness among the contacts. All instances of
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Figure 6. Incidence of measles in in the Croatia 1953-2011 period. Figure 7. Incidence of rubella in the Croatia 1976-2011 period.
transmission to contacts occurred after administration of
the first dose of MMR vaccine, not after the second dose.
For this reason, the MMR vaccine produced by the Insti-
tute was replaced by one of another producer for the first
dose in the schedule in 2009. In 2011, Institute’s MMR
was replaced by another vaccine for the second dose as
well, since the Institute discontinued its production.
DISCUSSION
Although the effect of vaccination can be measured in
various ways, the impact on disease burden is definitely
the most useful measure of vaccine effectiveness.
Comparing average disease incidence in the five-year
period prior to vaccine introduction or immediately
afterwards, depending on availability of data, and in the
last five-year period we can easily calculate the reduction
of disease incidence. Table 1 shows the reduction of
disease burden expressed as a rate.
The table clearly shows a remarkable reduction in
disease burden of vaccine-preventable disease. However,
in order to clarify if this reduction of disease burden is a
consequence of immunization or some other factors, it is
best to compare the incidence trend of a vaccine pre-
ventable disease with the incidence trend of another
disease with similar transmission patterns against which
vaccination is not performed or available, provided that
data on both diseases are collected through the same
information system and in the same manner.
A good example for comparison are measles and
chickenpox, two viral diseases with a high basic repro-
ductive index, both spread by the same respiratory route,
to which susceptibility is universal in an non-immune
population. Vaccination against measles with two doses
is mandatory since 1968 and vaccination coverage has
reached rates higher than 95%, while vaccination against
chickenpox is not included in the immunization sche-
dule, has not been widely accepted as facultative vacci-
nation and the coverage in children is estimated to be
lower than 1%.
Figure 9. illustrates incidence trends of measles and
chickenpox in Croatia since the time when reporting of
these diseases has become mandatory.
A five-year moving average is added to the figure in
order to smoothen the lines that illustrate the incidence
of both diseases, and the y-axis scale is logarithmic in
order to better show the dynamics (speed) of the change
in incidence.
It is obvious from Figure 9 that a significant and rapid
decrease in measles incidence followed the introduction
of vaccination, while the existing, but much slower de-
crease in chickenpox incidence would need hundreds of
years with this trend to reach the level measles have
reached in some thirty years.
Similarly, if we compare the speed of reduction in
poliomyelitis incidence with hepatitis A incidence, two
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Figure 8. Incidence of mumps in Croatia in the 1976-2011 period.
TABLE 1
Reduction of vaccine-preventable disease burden in Croatia.
Disease Average annual incidence Reduction of incidence (%)




Diphtheria 1 133 0 100
Tetanus 186 4 98
Pertussis 7 393 95 99
Poliomyelitis 219 0 100
Measles 15 183 14 >99
Rubella 11 248 8 >99
Mumps 8 569 53 99








diseases with a comparable mode of transmission, as
illustrated in Figure 10, it is clear that the rate of disease
reduction is much faster in case of poliomyelitis.
Similarly to the previous figure, five-year moving aver-
ages of poliomyelitis and hepatitis A incidence are added
in Figure 10, in order to smoothen the trend line. If only
improved sanitation, personal hygiene, and living con-
ditions were responsible for the elimination of polio-
myelitis, as they are for control of hepatitis A, the rate of
reduction would be similar for both diseases and the
trend lines should be more or less parallel. It is obvious
that the trend line of poliomyelitis is steeper than the one
of hepatitis A, indicating that immunization accelerated
the reduction of incidence.
Based on these analyses of incidence trends of vac-
cine-preventable diseases, it is quite reasonable to con-
clude that using the Institute’s vaccines and maintaining
high vaccination coverage in the national immunization
schedule resulted in great reduction of disease burden in
Croatia.
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Figure 9. Incidence trends of measles and chickenpox in Croatia.
Figure 10. Incidence trends of poliomyelitis and hepatitis A in Croatia.
